If approved, Dupixent would be the first biologic medicine approved in the region to treat these patients. The European Commission's final decision on the dupixent application is expected in the coming months, Regeneron said.
Price: 310.67, Change: +5.59, Percent Change: +1.83
|Avinger Prices More Than 3.18 Mln Shares at $1.18 Ea...|
|AbbVie (ABBV) Insider Makes Significant Share purcha...|
|Insiders at Snap (SNAP) Make Significant Stock Sales...|
|Insider Sales at Tabula Rasa Healthcare (TRHC) Exten...|
|Goosehead Insurance (GSHD) Insider Makes Significant...|